SageView Advisory Group LLC Buys New Position in AstraZeneca PLC (NASDAQ:AZN)

SageView Advisory Group LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,495 shares of the company’s stock, valued at approximately $436,000.

Other institutional investors have also added to or reduced their stakes in the company. Beaird Harris Wealth Management LLC boosted its holdings in shares of AstraZeneca by 8.9% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock worth $125,000 after buying an additional 151 shares in the last quarter. Bryn Mawr Capital Management LLC lifted its holdings in shares of AstraZeneca by 0.3% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock worth $4,167,000 after purchasing an additional 164 shares in the last quarter. Drive Wealth Management LLC lifted its holdings in shares of AstraZeneca by 4.5% in the 4th quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock worth $263,000 after purchasing an additional 170 shares in the last quarter. GM Advisory Group LLC lifted its holdings in shares of AstraZeneca by 3.5% in the 4th quarter. GM Advisory Group LLC now owns 5,015 shares of the company’s stock worth $338,000 after purchasing an additional 170 shares in the last quarter. Finally, Glenview Trust co lifted its holdings in shares of AstraZeneca by 3.8% in the 3rd quarter. Glenview Trust co now owns 4,724 shares of the company’s stock worth $320,000 after purchasing an additional 174 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. The Goldman Sachs Group began coverage on AstraZeneca in a report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price on the stock. BMO Capital Markets increased their target price on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Finally, Argus increased their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $88.00.

AstraZeneca Trading Down 1.1 %

NASDAQ AZN opened at $78.42 on Thursday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The firm has a market capitalization of $243.14 billion, a P/E ratio of 38.44, a PEG ratio of 1.41 and a beta of 0.48. The business has a fifty day simple moving average of $75.90 and a 200 day simple moving average of $69.60. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $11.92 billion. On average, analysts predict that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.